Vallon Pharmaceuticals (VLON) Key Ratios
$8.59
As on 24-Apr-2023 09:30EDT
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -71.84 | 9.64 | 28.16 | -158.12 | -- |
| Net Profit | -11.08 | 7.93 | 25.38 | -47.60 | -- |
| EPS | 97.49 | 98.60 | 64.87 | -8.60 | -- |
| Book Value | -- | -- | -72.96 | -21.41 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -4,788.00 | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -386.39 | -- | -397.82 | -176.86 | -430.43 |
| Return on Capital
| -319.26 | -- | -- | -173.27 | -385.79 |
| Return on Assets
| -167.82 | -- | -113.39 | -115.58 | -202.20 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | 0.03 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
-173.27
|
-385.79
|
-398.72
|
-209.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-397.82
Lower than Peers by 357.42
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
-397.82
|
-176.86
|
-430.43
|
-551.88
|
-230.94
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-113.39
Lower than Peers by 82.42
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
-113.39
|
-115.58
|
-202.20
|
-185.67
|
-158.20
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
--
|
--
|
-4,788.00
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
--
|
--
|
-4,856.00
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
--
|
-1.00
|
--
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
28.16
Higher than Peers by 28.96
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
28.16
|
25.18
|
-93.38
|
-51.79
|
26.86
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
25.38
Higher than Peers by 32.68
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
25.38
|
23.17
|
-93.41
|
-24.91
|
9.86
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
64.87
Higher than Peers by 50.22
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
64.87
|
0.48
|
-0.62
|
-0.48
|
--
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-99.99
Lower than Peers by 89.81
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
-99.99
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
--
|
0.03
|
-0.23
|
0.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
--
|
0.02
|
-0.10
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.15
Lower than Peers by 2.66
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
3.15
|
2.29
|
3.32
|
0.30
|
4.86
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
3.15
Lower than Peers by 2.54
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
3.15
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-149.78
Lower than Peers by 147.69
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
-149.78
|
-266.46
|
-578.69
|
-140.82
|
--
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
--
|
--
|
0.04
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
-0.41
|
-4.34
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.84
Lower than Peers by 4.34
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
0.84
|
1.26
|
7.00
|
--
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.53
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
0.53
|
0.13
|
-3.66
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
5
Lower than Peers by 141
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
|
5
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|